Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 65.67 +3.75 (6.06%)
price chart
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK (Reuters) - Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol to Buy Amylin in $5.3 Billion Deal  Wall Street Journal
Why Bristol And Astra Teamed Up To Buy Amylin In Unique $7 Billion Deal  Forbes
Related articles »  
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Related articles »  
Interim results from Bristol-Myers Squibb's BMS-936558 Phase 1 study on ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with ...
Related articles »  
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL´┐Ż (dasatinib) in Philadelphia ...
Related articles »  
Terminally ill patients should have access to last-chance therapies
... because of tumours in his brain. His oncologist recommends that he be given the drug, BMS-936558, saying it may help. But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and ...
Legalize pure ecstasy and sell it like alcohol, BC health chief says
DuPont, Bristol-Myers-Squibb, Novartis, etc. ... Mr. Freeh served as Vice Chairman, General Counsel, Corporate Secretary and Ethics Officer to MBNA Corporation, a bank holding company, from 2001 until its acquisition by Bank of America in January 2006.
Related articles »  
Pfizer, Bristol-Myers' Eliquis Drug Fails to Win FDA Approval
June 25 (Bloomberg) -- Pfizer Inc. and Bristol-Myers Squibb Co. failed to gain approval of their top experimental drug, the blood thinner Eliquis, from U.S.
FDA rejects blockbuster Eliquis bid, asks Pfizer, BMS for trial clarification  FierceBiotech
FDA delays decision on Pfizer, Bristol-Myers drug Eliquis  MassLive.com
Related articles »  
How to Profit From Bristol-Myers Squibb's New Cancer Drugs
Bristol-Myers Squibb announced this week that not one but two of its experimental immunotherapy drugs, not chemotherapy drugs, immunotherapy, have shown amazing results in advanced stages of several types of cancer, and the results are long lasting.
Related articles »